You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明合聯(02268.HK)中期擁有人應占純利4.88億元 同比勁增175.5%
格隆匯 08-20 21:43

格隆匯8月20日丨藥明合聯(02268.HK)公吿,截至2024年6月30日止6個月,集團取得了驕人的業績。集團收益及毛利亦呈現強勁增長,分別同比增長67.6%及133.4%至人民幣16.65億元及人民幣5.35億元。此外,截至2024年6月30日止6個月,公司擁有人應占純利增至人民幣4.88億元,同比增長175.5%,而截至2024年6月30日止6個月,公司擁有人應占經調整純利亦增長強勁,增長至人民幣5.3億元,相當於同比增長146.6%。董事會不建議就截至2024年6月30日止6個月派付任何中期股息。

集團致力於不斷增強平台,推動和改變生物偶聯藥物行業的發展,賦能全球生物製藥合作伙伴並使全球患者受益。憑藉全面的"一體式"生物偶聯藥物平台,覆蓋生物偶聯藥物CRDMO服務的關鍵方面,包括生物偶聯藥物、單克隆抗體中間體和生物偶聯藥物相關連接子及有效載荷的發現、工藝開發及GMP生產,集團賦能客户在開發過程的任何階段推進其項目。於報吿期內,集團的服務基於"賦能、跟隨並贏得分子"的策略,持續滿足客户╱合作伙伴開發生物偶聯藥物的需求。 

公司憑藉卓越的表現連續兩年獲得WorldADC獎提名,並於2023年榮獲"最佳CDMO冠軍"獎。集團的持續發展以及屢獲殊榮,凸顯了藥明合聯在為ADC及更廣泛的生物偶聯藥物提供與技術創新相結合的綜合服務以及強大的化學、製造與管制(CMC)專業知識方面處於全球領先地位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account